Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04249622 · ClinicalTrials.gov registry record · Phase 2
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04249622: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT04249622 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04249622, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial studies how well rifaximin works for the treatment of gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2 positive breast cancer. Rifaximin may reduce the incidence and severity of pertuzumab induced gastrointestinal toxicities without interrupting or delaying the chemotherapy schedule.
Interventions
- OTHER Questionnaire Administration
- OTHER Best Practice
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2022-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04249622
The ClinicalTrials.gov registry entry for NCT04249622 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT04249622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04249622 about?
NCT04249622 is a clinical study titled "Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer". This phase II trial studies how well rifaximin works for the treatment of gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2 positive breast cancer. Rifaximin may reduce the incidence and severity of pertuzumab induced gastrointestinal toxicities withou...
What is the current status of trial NCT04249622?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-09-18. Estimated completion is 2022-12-27.
What interventions are being tested in trial NCT04249622?
The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT04249622?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.